Cardiovascular risk is independently increased by abnormalities in low-density and high-density lipoprotein-cholesterol and triglycerides. Many patients have more than one lipid abnormality. Combination therapy with lipid-modifying agents offers an important therapeutic option for improving the overall lipid profile. Combinations have demonstrated additive efficacy and significant reductions in coronary events. Health care providers who understand combination therapy can play an important role in the effective use of these treatment options for dyslipidemia.
|Idioma original||English (US)|
|Número de páginas||11|
|Publicación||P and T|
|Estado||Published - feb 1 2004|
ASJC Scopus subject areas
- Pharmacology (medical)